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Abstract. Traditionally, non-cancer diseases are not consid-
ered as health risks following exposure to low doses of ionizing 
radiation. Indeed, non-cancer diseases are classified as deter-
ministic tissue reactions, which are characterized by a threshold 
dose. It is judged that below an absorbed dose of 100 mGy, no 
clinically relevant tissue damage occurs, forming the basis for 
the current radiation protection system concerning non-cancer 
effects. Recent epidemiological findings point, however, to an 
excess risk of non-cancer diseases following exposure to lower 
doses of ionizing radiation than was previously thought. The 
evidence is the most sound for cardiovascular disease (CVD) 
and cataract. Due to limited statistical power, the dose-risk 
relationship is undetermined below 0.5 Gy; however, if this 
relationship proves to be without a threshold, it may have 
considerable impact on current low-dose health risk estimates. 
In this review, we describe the CVD risk related to low doses of 
ionizing radiation, the clinical manifestation and the pathology 
of radiation-induced CVD, as well as the importance of the 
endothelium models in CVD research as a way forward to 
complement the epidemiological data with the underlying 
biological and molecular mechanisms.
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1. Cardiovascular disease risk related to low doses of ionizing 
radiation
Recognition of radiation-related cardiovascular disease 
(CVD) risk. The recognition that exposure of the heart and 
the vasculature to high doses of ionizing radiation can cause 
CVD began in the late 1960s (1). This was mainly related to 
the clinical observation of cardiovascular complications in 
radiation-treated survivors of Hodgkin's lymphoma and other 
childhood cancers. Later, larger-scale epidemiological studies 
found a clear association between therapeutic doses of thoracic 
irradiation and an increased risk of CVD in these long-term 
cancer survivors, confirming the earlier observations (2).
An excess risk of CVD was also observed after post- 
operative radiotherapy for breast cancer. In these patients, a part 
of the heart received accumulated doses of ≥40 Gy (fraction-
ated 20x2 Gy). After correction for fractionation effects using 
the linear quadratic model and an α/β ratio of 1-3 Gy, deter-
mined in experimental studies in the rat heart, Schultz-Hector 
and Trott calculated that this corresponds to equivalent single 
doses to the total heart of approximately 1-2 Gy (3). The Early 
Breast Cancer Trialists' Collaborative Group performed a meta- 
analysis on mortality data of >30.000 breast cancer patients 
15 years after treatment. The mortality of heart disease was 
increased by 27% in patients treated with surgery and subse-
quent radiotherapy compared to patients treated with surgery 
alone (4). The evaluation of long-term mortality in breast cancer 
survivors may however be influenced by the varying prognosis 
of the different treatment regimens (surgery vs. radiotherapy). 
This can be circumvented by comparing women irradiated 
for left-sided tumours with women irradiated for right-sided 
tumours. Cardiac radiation doses are larger in radiotherapy 
patients with left-sided tumours than in radiotherapy patients 
with right-sided tumours (5). An analysis of 308,861 women 
with breast cancer registered in the Surveillance, Epidemiology 
and End-Results cancer registries database from the United 
States revealed an increased heart disease mortality ratio for 
Cardiovascular diseases related to ionizing radiation: 
The risk of low-dose exposure (Review)
BJORN BASELET1,2*,  CHARLOTTE ROMBOUTS1,3*,  ABDERRAFI MOHAMMED BENOTMANE1,   
SARAH BAATOUT1,3  and  AN AERTS1
1Radiobiology Unit, Institute for Environment, Health and Safety, Belgian Nuclear Research Centre (SCK•CEN), Mol;  
2Pole of Pharmacology and Therapeutics, Institute of Experimental and Clinical Research, University of Louvain 
Medical School, Brussels; 3Department of Molecular Biotechnology, Ghent University, Ghent, Belgium
Received June 1, 2016;  Accepted September 7, 2016
DOI: 10.3892/ijmm.2016.2777
Correspondence to: Professor Sarah Baatout, Radiobiology Unit, 
Institute for Environment, Health and Safety, Belgian Nuclear Research 
Centre (SCK•CEN), Mol, Boeretang 200, 2400 Mol, Belgium
E-mail: sbaatout@sckcen.be
*Contributed equally
Key words: cardiovascular disease, ionizing radiation, low dose 
research, endothelial cells, radiobiology
BASELET et al:  LOW DOSE IONIZING RADIATION EXPOSURE AND CARDIOVASCULAR DISEASE1624
women irradiated for left-sided breast cancer compared to those 
irradiated for right-sided breast cancer (6). A study related to 
72,134 women diagnosed with breast cancer in Denmark and 
Sweden during the years 1976-2006 and a follow-up of 30 years 
revealed an increased risk of ischemic heart disease (IHD), 
pericarditis and valvular disease in irradiated women with left-
sided tumours (mean cardiac dose 6.3 Gy) compared to those 
with right-sided tumours (mean cardiac dose 2.7 Gy) (7).
In addition, patients with benign diseases, such as peptic 
ulcers treated with radiotherapy form interesting study cohorts. 
For instance, coronary heart disease-related mortality was 
compared between peptic ulcer patients treated with radio-
therapy (n=1859) and those treated by other means (n=1860) (8). 
The calculated received volume-weighted cardiac doses ranged 
from 1.6 to 3.9 Gy and the portion of the heart directly in the 
radiation field received doses of 7.6-18.4 Gy. A significantly 
increased risk of coronary heart disease-related mortality was 
observed with the increasing dose. Only recently, various epide-
miological findings, in particular from the Japanese atomic 
bomb survivors, have raised awareness of possible CVD risk 
following exposure to low and moderate doses of radiation (3). 
Below an overview is given of the major epidemiological find-
ings related to CVD risk following low-dose exposure.
Low-dose exposed epidemiological cohorts
Classification of CVD in epidemiology. Reviewing the epide-
miological literature related to CVD and low-dose ionizing 
radiation is complicated by the different classifications of 
CVD. Moreover, all types of CVD are often pooled in one diag-
nosis in epidemiological studies. This hampers the thorough 
understanding of radiation-related CVD risk, and distinction 
should be made between the different clinical manifestations. 
In addition, many epidemiological studies face the problem of 
misclassification of the cause of death, except for stroke, for 
which the diagnosis tends to be reasonably good (9). In fact, 
stroke is not considered to be a CVD, but a circulatory disease 
since it involves the blood circulation in the brain and is unre-
lated to the heart. It is defined by brain injury, which occurs 
when a blood vessel in the brain ruptures, leading to haemor-
rhage, or when a blood vessel is blocked, leading to ischemia 
following the loss of blood supply in the brain area of concern.
Patients treated with radiation therapy (RT). External 
beam RT for breast cancer, Hodgkin's lymphoma, or even 
peptic ulcer disease in the early days often involves some inci-
dental exposure of the heart. There are studies pointing to late 
secondary cardiovascular effects due to this scattered radiation 
exposure. Long-term follow-up was shown to be essential, as 
the cardiovascular complications may manifest years after the 
completion of RT.
Most peptic ulcers are caused by an infection with a type 
of bacteria known as Helicobacter pylori and are nowadays 
treated, at least partly, with antibiotics. However, mid-last 
century peptic ulcer disease patients were irradiated. Peptic 
ulcer disease patients treated with RT (n=1859) or by other 
means (n=1860) at the University of Chicago Medical Center 
between 1936 and 1965, were followed through 1997 by 
Carr et al (8). The irradiated patients received volume-weighted 
cardiac doses ranging from 1.6 to 3.9 Gy and the portion of 
the heart directly in the radiation field received doses of 
7.6-18.4 Gy. The observed numbers of cause-specific deaths 
were compared with the expected numbers from the general 
population rates. Greater than expected coronary heart disease-
related mortality was observed among the irradiated patients. 
The excess coronary heart disease risk in patients who received 
RT for peptic ulcer disease decades before indicates the need 
for long-term follow-up of CVD after chest RT.
Over the last half century, RT has evolved to become one 
of the cornerstones of treatment for various types of cancer. 
It is estimated that >50% of patients with cancer are treated 
with radiotherapy. Along with the development of novel 
chemotherapeutic agents, RT has revolutionized the prognosis 
of patients with various types of cancer. Cancers during child-
hood and adolescence are now more and more successfully 
treated and these patients go on to live an active and normal 
adult life, as evident by an increasing number of cancer survi-
vors. Late cardiovascular effects are often observed in cancer 
survivors (10). Hodgkin's lymphoma was the earliest paradigm 
for the study of radiation-induced vascular disease. A first case 
report was published in 1924 about histological changes in the 
human heart after irradiation for Hodgkin's lymphoma (11). 
Amongst Hodgkin's lymphoma patients who received radia-
tion, CVD is of the most common causes of death. Studies have 
shown that these patients have an increased risk of coronary 
artery disease, valvular heart disease, congestive heart failure, 
pericardial disease and sudden death. The risk is particularly 
high in patients treated before the age of 40 years (12-15).
In addition, RT for breast cancer often involves some inci-
dental exposure of the heart to ionizing radiation. Darby et al (16) 
conducted a population-based case-control study of major 
coronary events (i.e., myocardial infarction, coronary revascu-
larization, or death from IHD) in 2,168 women who underwent 
radiotherapy for breast cancer between 1958 and 2001 in 
Sweden and Denmark. The overall average of the mean doses 
to the whole heart was 4.9 Gy (range, 0.03-27.72). The rates of 
major coronary events increased linearly with the mean dose to 
the heart by 7.4%/gray [95% confidence interval (CI), 2.9-14.5; 
P<0.001], with no apparent threshold. The increase began 
within the first 5 years after radiotherapy and continued into 
the third decade after radiotherapy.
Due to improvements in radiation techniques (e.g., breathing- 
adapted RT, CyberKnife), the risk of cardiovascular complica-
tions in relation to radiation are uncertain, but may be expected 
to decline. However, patients with classical risk factors, such 
as hypertension, smoking and hyperlipidaemia may be at an 
increased risk of radiation-related cardiovascular complica-
tions, and these risk factors should be treated aggressively (10). 
Younger patients should be screened, as this patient population 
at risk usually has a considerable life expectancy.
Survivors of the atomic bombings of Hiroshima and 
Nagasaki. The most informative cohort is the Life Span 
Study (LSS), consisting of 120,321 exposed and non-exposed 
individuals selected from respondents to the national census of 
Japan in 1950 calling for survivors exposed to the bombings in 
Hiroshima and Nagasaki, and from residential surveys in the 
cities after the national census. Mortality in this population has 
been investigated since the 1950s by collecting information 
through the national population registry (koseki) and death 
certificates obtained throughout Japan. Cancer incidence data 
was available from population-based cancer registries since 
1957 in Hiroshima and since 1958 in Nagasaki (17). Next to 
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the availability of these data, the large size, the presence of 
both genders and all ages, and well-characterized individual 
dose estimates makes this cohort a valuable source for risk 
estimation. Another cohort, the Adult Health Study (AHS), 
was established in 1958 and consists of 19,961 subjects from 
the LSS cohort. These survivors underwent biennial health 
examinations, which provided additional clinical and sub-
clinical information to the death and cancer registries data. In 
this way, disease morbidity for a variety of conditions can be 
investigated (18).
Preston et al evaluated non-cancer mortality based on the 
LSS report 13 published by the Radiation Effects Research 
Foundation (RERF), which covers the time period between 
1950-1997 (19). In their study, the weighted colon doses from 
the DS86 dosimetry system were used for individual dose 
estimates. Only the period between 1968-1997 was included to 
account for the ‘healthy survivor’ selection effect. Individuals 
had to be alive in 1950 to enter the LSS cohort and have thus 
survived the difficult conditions after the bombing, which means 
that the health experience of this cohort may not be typical for 
a normal population. This is reflected as a decrease in non-
cancer mortality during 1950-1960 in the LSS members that 
received doses below 2 Sv, as shown by Shimizu et al (20). This 
‘healthy survivor’ selection effect had largely disappeared by 
the mid-1960s. To exclude this confounding effect, Preston et al 
advised to restrict the analyses to proximal survivors who 
were within 3 km of the hypocenter of the bombing, and to a 
follow-up period starting from 1968 (19). Based on the linear 
no-threshold model (LNT) model, excess relative risk (ERR) 
estimates were calculated to be 0.17 with 90% CI (0.08-0.26) 
for heart disease and 0.12 (90% CI, 0.02-0.22) for stroke, for the 
period between 1968-1997 (19).
Shimizu et al evaluated ERR of mortality from heart disease 
and stroke in the LSS cohort with a follow-up of 53 years (1950-
2003) (21). For individual dose estimates, weighted colon 
doses (Gy) from the DS02 dosimetry system were used. In 
addition, the authors obtained, by a mail survey, information 
regarding sociodemographic (education, occupation type), 
lifestyle (smoking, alcohol intake) and health variables (obesity, 
diabetes mellitus) from 36,468 members of the LSS cohort. This 
allowed them to evaluate the effect of these confounding factors 
on ERR estimates. It should be noted that they included the full 
follow-up period from 1950-2003 and all survivors, thus not 
taking into account the ‘healthy survivor’ selection effect. For 
the detrimental health outcomes of heart diseases and stroke 
there is, however, no healthy survivor selection effect. This has 
recently been confirmed by Schöllnberger et al (23) following 
the comments of Little et al (22). Shimizu et al (21) found an 
ERR of 0.14 (95% CI, 0.06-0.23) for heart disease and an ERR 
of 0.09 (95% CI, 0.01-0.17) for stroke based on the LNT model. 
Whereas the LNT model fitted best the data for heart disease, 
the quadratic model was best to fit the data for stroke (Fig. 1). 
The latter model implies relatively little risk at lower doses. 
Indeed, the calculation of ERR for stroke over restricted dose 
ranges revealed an ERR of 0.03 (95% CI, -0.10-0.16) for 0-1 Gy 
and -0.07 (95% CI, -0.28-0.16) for 0-0.5 Gy. Furthermore, 
they showed that the association of dose with CVD risk in the 
LSS cohort is unlikely to be an artefact from confounding by 
sociodemographic, lifestyle or disease risk factors.
The above-mentioned studies have used the LSS cohort 
for CVD risk estimations. Takahashi et al examined the 
association with dose and the incidence of stroke in the AHS 
cohort (18). For their study, information of health examinations 
from the follow-up from 1980 onwards has been used, resulting 
in 9,515 AHS participants. For individual dose estimates, 
weighted colon doses (Gy) from the DS02 dosimetry system 
were used. In this study population, risk for haemorrhagic 
stroke was observed to increase with dose. This was across the 
full range of doses for men, while in women there seems to be 
a threshold of approximately 1.3 Gy.
Occupational exposure. Studies on radiation workers are 
of interest since they generally involve relatively low doses 
received over repeated exposures, although in some cases, 
accumulated doses may be high. Various studies have been 
performed, of which the most important will be discussed. 
The largest studied cohort consists of 275,000 nuclear industry 
workers from 15 countries, referred to as the 15-country 
study (24). The average cumulative dose received was 20.7 mSv. 
An overall increasing trend, although not significant, for 
circulatory disease mortality was observed. It was concluded 
that their findings are compatible with both no increased risk 
and with an increased risk comparable to that observed in 
A-bomb survivors. The Chernobyl liquidator cohort consisted 
of 61,017 individuals with an average cumulative dose of 
Figure 1. Radiation dose-response relationship (ERR/Gy) in the Life Span Study (LSS) cohort for death from stroke (left panel) and death from heart dis-
ease (right panel), showing linear-quadratic and linear functions. Shaded areas represent 95% confidence region for the fitted linear line. Error bars represent 
95% CI for each dose category risks and the bullet represents the point estimate of risk for each dose category. The participants were divided into several dose 
categories according to their weighted colon dose (in Gy, γ dose plus 10 times neutron dose) (21).
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0.109 Gy. An ERR/Gy of 0.41 (95% CI, 0.05-0.78) was found for 
IHD morbidity and 0.45 (95% CI, 0.11-0.80) for the morbidity 
of cerebrovascular diseases, though the outcomes were not 
adjusted for recognized risk factors such as excessive weight, 
hypercholesterolemia, smoking, alcohol consumption and 
others (25). A study by Muirhead et al revealed an increasing 
circulatory disease mortality risk with dose, which was border-
line significant, in the UK National Registry of Radiation 
Workers in the industrial and medical field (26). The average 
cumulative dose received was 24.9 mSv. This finding should, 
however, be interpreted with caution due to the lack of infor-
mation on confounding factors. Another large cohort consisted 
of 206,620 radiation workers in the industrial and medical 
field, registered in the National Dose Registry of Canada (27). 
The average exposure of all workers was 6.3 mSv, with large 
differences between males (10.6 mSv) and females (1.7 mSv). 
A significant increasing trend of circulatory disease mortality 
with dose was observed in males. Again, there is a lack of 
information on confounding factors and there is also incom-
pleteness of dose records. Finally, a recent publication studied 
a 34% increase in stroke incidence after a survey during the 
years 1994-2008 of a cohort of 90,957 radiologic technologists 
who worked with fluoroscopically guided interventional proce-
dures (28). In addition, mortality from stroke was also modestly 
elevated, although not statistically significant. No statistically 
significant excess risks of incidence or mortality were observed 
from any other cardiovascular disorders evaluated.
The Mayak cohort is of particular interest since it includes 
information both on mortality and morbidity, and information 
on confounding factors (29). In 1948, the first nuclear energy 
enterprise in Russia, Mayak Plutonium Association, became 
operational. Since 1948 the Mayak personnel undergo regular 
routine medical examinations. In addition, every 3-5 years 
a more detailed examination is carried out in a specialized 
hospital. This examination system led to a unique archive of 
medical data, which was used to create the ‘Clinic’ medical-
dosimetric database. In addition, from a dosimetric point of 
view, the database is sound. Individual dosimetry for external 
gamma exposure was introduced at the beginning of 1948 and 
for internal exposure during the 1960s (29). Complete data 
are available for 12,585 Mayak workers employed during the 
years 1948-1958 and followed-up until December 2000. The 
mean cumulated external dose was 0.91±0.95 Gy (99% percen-
tile 3.9 Gy) for men and 0.65±0.75 Gy (99% percentile 2.99 Gy) 
for women. In this cohort, a significant increasing trend in 
IHD morbidity was observed with the increasing total external 
dose [ERR/Gy=0.11 (95% CI, 0.049-0.168)]. The influence of 
confounding factors on this trend was minimal (30). A follow-up 
study involved the analysis of a cohort including 18,763 Mayak 
workers with an additional follow-up of 5 years (31). Overall, 
risk estimates for IHD were similar to the earlier study [ERR/
Gy=0.10 (95% CI, 0.045-0.153)]. Remarkable though, a statisti-
cally significant decrease in IHD incidence was found among 
workers exposed to external doses of 0.2-0.5 Gy compared to 
workers exposed to external doses below 0.2 Gy. This decreased 
risk is heavily influenced by the observations in female workers. 
The authors further noted that this finding should be inter-
preted with caution since it has never been reported in other 
studies. The latter analysis was further updated and extended 
by looking at the lag-time to progression of IHD and by using 
the updated dosimetry system MWDS-2008 (32) . In that study, 
it was observed that the main detrimental effects of external 
radiation exposure occurred after >30 years. In addition, a 
statistically significant risk was observed in men for mortality 
caused by IHD [ERR/Gy=0.09 (95% CI, 0.02-0.16)] while the 
risk was not significant for women. Recently, Azizova et al 
published a study regarding incidence and mortality from IHD 
in an extended cohort of 22,377 Mayak workers first employed 
during the years 1948-1982 and followed-up to the end of 
2008 (33). Risk analysis demonstrated a significant increasing 
trend in IHD incidence, but not mortality, with total dose from 
external gamma-rays after having adjusted for non-radiation 
factors and dose from internal radiation. ERR/Gy for IHD 
incidence in males was 6-fold higher than in females. In addi-
tion, a significant increasing linear trend was observed in IHD 
mortality, but not incidence, with total absorbed dose from 
internal alpha radiation to the liver after having adjusted for 
non-radiation factors and doses from external gamma-rays.
In the same Mayak population, the incidence of and 
mortality from cerebrovascular disease was studied (34). The 
cohort consisted of 22,377 workers from the extended Mayak 
worker cohort that was followed-up to the end of 2008. In 
this study, the workers were exposed to a mean cumulated 
external dose of 0.54±0.76 Gy (95% percentile 2.21 Gy) for 
men and 0.44±0.65 Gy (95% percentile 1.87 Gy) for women. 
After correction for confounding factors, a significant 
increasing trend in cerebrovascular disease incidence was 
observed with increasing total external dose [ERR/Gy=0.46 
(95% CI, 0.37-0.57)]. In addition, the authors showed that the 
cerebrovascular disease incidence was significantly higher in 
workers with a total external dose >0.1 Gy when compared 
to those exposed to lower doses. Restricting the analysis to a 
subcohort with negligible internal exposure for incidence of 
cerebrovascular disease supports a dose response sub-linear for 
low doses for incidence of cerebrovascular disease (35). In that 
study, the excess relative risk/dose was confirmed to be signifi-
cantly higher for the incidence of cerebrovascular disease in 
comparison to cerebrovascular disease mortality and the inci-
dence of stroke. The authors hypothesized that this difference 
was based on the complex nature of cerebrovascular diseases. 
The incidence was mainly related to chronic forms of cerebro-
vascular disease, while the mortality was mostly caused by the 
acute forms. Finally, having a young age during exposure was 
observed to be an important, aggravating modifier of radiation 
risk for incidence of cerebrovascular disease and stroke.
It should be noted that apart from the classical vascular-
related confounding factors, occupational studies have to deal 
with the ‘healthy worker’ selection effect, similar to the ‘healthy 
survivor’ selection effect in A-bomb survivors. The ‘healthy 
worker’ selection effect occurs when workers who are healthier 
and have lower mortality and morbidity rates are selectively 
retained in the workplace, as such accumulating higher doses. 
One can adjust for this confounding factor by considering the 
duration of employment as a confounding factor in the analysis, 
as done in the 15-country study (24).
Meta-analysis of epidemiological data. The Advisory 
Group on Ionizing Radiation (AGIR) from the Health 
Protection Agency reviewed the available epidemiological 
data for low- and moderate-dose exposure in 2010. Taking 
all the studies together, they reported a small, but statisti-
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cally significant overall ERR/Gy of 0.09 (95% CI, 0.07-0.12). 
AGIR noticed, however, that there was a lot of heterogeneity 
in risk estimates of the different studies included in their meta- 
analysis (9). Little et al recently extended this meta-analysis (36). 
They estimated excess risks for four subgroups of circulatory 
disease, classified according to the ‘International Classification 
of Diseases, 10th revision’: IHD, non-IHD, cerebrovascular 
disease and all other circulatory diseases. A significant effect 
of heterogeneity between the different studies was found for 
cerebrovascular disease and other circulatory diseases, but not 
for IHD and non-IHD. ERR were calculated based on the LNT 
model, which implicitly assumes a linear association of CVD 
risk at low doses and dose rates. They noted that this assump-
tion is reasonable since there is little evidence for non-linearity 
in the Japanese atomic bomb survivors and Mayak workers 
data. Furthermore, at least for IHD and non-IHD, the ERR/Sv 
was consistent between the Japanese atomic bomb survivors, 
Mayak workers and other occupational cohorts (36). Although 
it should be noted that Schöllnberger et al and others advo-
cate for the consideration and testing of other dose-response 
models for non-cancer effects (32,37). To conclude, the overall 
consensus of the above-mentioned studies is that there is a 
significant elevated CVD risk for doses >0.5 Gy (9,38).
Epidemiology alone is not the answer. CVD is the leading 
cause of mortality and morbidity and accounts for 30-50% of 
all deaths in most developed countries. It is a multifactorial 
disease with many risk factors, such as lifestyle and other 
personal factors (39). The most established risk factors include 
the male gender, elevated low-density lipoprotein (LDL) 
levels, smoking, hypertension, a family history of premature 
coronary disease and diabetes mellitus (40). Epidemiological 
studies, as presented above, have limited statistical power 
to detect a possible excess risk of CVD following low-dose 
exposure (<0.5 Gy), due to the high background level of CVD 
in the population as a whole and many potentially confounding 
risk factors (9). For example, it has been calculated that, if 
the excess risk is in proportion to dose, a cohort of 5 million 
individuals would be needed to quantify the excess risk of a 
10 mSv dose (41). Other factors that have an influence on epide-
miological results are the distribution of the dose range, the 
accuracy of dosimetry, the duration of follow-up after exposure 
and correct assignment of cause of mortality, as reviewed by 
Borghini et al (42).
Although epidemiological studies have led to a better insight 
in radiation-related CVD risk, there are still many uncertain-
ties that need to be clarified. These include whether there is 
a threshold dose; whether the latency of CVD development is 
dependent on the dose; the identification of the sensitive targets 
in the heart and vasculature; whether exposure has an impact 
on CVD incidence or progression, or both; and the exact impact 
of acute, fractionated or chronic exposure on risk estimates. For 
an accurate dose risk assessment, these questions need to be 
answered.
Classical epidemiological studies, as described above, do 
not provide all the needed insight to answer these questions. 
A more targeted approach, such as the integration of epide-
miology and biology is required. For example, the assessment 
of subclinical endpoints and other cardiovascular biomarkers 
by functional imaging in patients receiving radiotherapy may 
provide insight into the development and progression of CVD 
following radiation exposure (39,42). Single-photon emis-
sion computed tomography (SPECT) or positron emission 
tomography (PET) imaging of micro-vascular perfusion has 
already been applied in breast cancer studies. The outcome 
differed between studies. For instance, whereas in one study 
perfusion defects were observed within 6-12 months after 
radiotherapy (43), no significant differences in perfusion defects 
were found in another study (44). In addition, the evaluation of 
cardiovascular biomarkers in patients receiving radiotherapy 
may be useful. For instance, elevated levels of N-terminal pro-
B-type natriuretic peptide (NT-proBNP) in the blood (45,46) 
have been shown to be predictive for heart failure and/or CVD 
mortality across a broad range of individuals (47). Higher values 
of NT-proBNP were found in patients treated with radiotherapy 
for left-sided breast cancer compared to patients treated with 
other means (48).
Next to epidemiology, radiobiological research is essential 
for understanding CVD risk specifically in the low-dose region. 
Since epidemiological findings for low and moderate doses are 
suggestive and not persuasive, their use in dose risk assessment is 
limited. A thorough understanding of the biological and cellular 
mechanisms gathered through experimental studies is thus 
needed to complement the epidemiological findings. Once we 
have a comprehensive understanding of the underlying biological 
mechanisms, biologically-based dose-response models can be 
included in the dose risk assessment. This may prove to be bene-
ficial for an accurate risk estimation in the low-dose region (49).
Societal concern. The possible excess risk of CVD following 
exposure to low doses is of great societal concern. According 
to the ICRP, a dose of 0.5 Sv may lead to approximately 1% 
of exposed individuals developing cardiovascular or cerebro-
vascular disease >10 years following exposure, in addition to 
the 30-50% suffering from disease without being exposed to 
ionizing radiation (50). Although the assumed risk is rather 
small, it may have serious implications for public health. 
Indeed, seeing the high background rate of CVD, the absolute 
number of excess cases would be substantial (42).
Various issues, such as occupational radiation exposure, the 
future of nuclear power, manned space flights and the threat 
of radiological terrorism, call for a thorough understanding 
of low-dose health risks (41). The main concern is, however, 
the increasing use of ionizing radiation for diagnostic medical 
purposes (Fig. 2) (51). For instance, since 1993, the number of 
computed tomography (CT) scans has quadrupled in the US 
and similar trends are observed in Europe (52).
In particular, the increased use of non-invasive cardio-
vascular imaging techniques, such as cardiac CT scans and 
myocardial perfusion imaging with radionuclides, are of 
importance (53). Indeed, effective doses range from 1 to 20 mSv 
depending on the procedure (Table I) (58). Although one 
cannot deny the huge health benefits of these improved diag-
nostic procedures, concerns are raised regarding the ‘overuse’ 
and potential associated health risks (54). For example, it has 
been observed that 14-22% of cardiac imaging tests are inap-
propriate in the US (55,56).
Radiation protection of patients is not based on dose 
limits, but on the principle of justification that states that the 
benefits and risks from the use of ionizing radiation should 
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be carefully evaluated. However, this risk/benefit balance 
is highly patient-dependent and the decision for the use of a 
specific imaging test relies on the physician's judgment. Several 
guidelines have been published by various societies, such as the 
European Society of Cardiology and the American College of 
Cardiology Foundation, to aid in this decision (53,57). These 
guidelines provide information regarding the accuracy of the 
tests, the usefulness of the information obtained from the test, 
and also regarding the risks of the tests including those related 
to adverse radiation health effects. In addition, the implemen-
tation of informed consent, in which the possible risks are 
communicated to the patient and in view of his or her consent, 
will stimulate physicians to more carefully balance benefits and 
risks of a specific imaging procedure (54,58). Furthermore, the 
development and implementation of dose-lowering techniques 
may be beneficial not only for the patient (59), but also for 
Table I. Overview of typical ionizing radiation doses in cardiac imaging procedures.
 Representative Range of reported Administered
 effective dose effective dose activity
Examination value (mSv) values (mSv) (MBq)
Chest X-ray posteroanterior and lateral 0.1 0.05-0.24 N/A
Diagnostic invasive coronary angiogram   7 2-16 N/A
Coronary CT angiogram
  64-slice multidetector, retrospective gating 12 9-19 N/A
  64-slice multidetector, reduced tube voltage (100 kVp)   6 3-8 N/A
  64-slice multidetector, prospective triggering   3 2-4 N/A
  Dual-source high pitch <1 <1 N/A
  264 or 320 multidetector row CT   4 2-8 N/A
Nuclear medicine studies
  Myocardial perfusion
    Sestamibi (1-day) stress/rest 12 N/A 1480
    Tetrofosmin (1-day) stress/rest 10 N/A 1480
    Thallium stress/redistribution 29 N/A   130
    Rubidium-82 rest/stress 10 N/A 2960
  Myocardial viability
    PET F-18 FDG 14 N/A   740
    Thallium stress/reinjection 41 N/A   185
CT, computed tomography; FDG, fluorodeoxyglucose; N/A, not applicable; PET, positron emission photography. This table has been adapted 
from a previous study (58).
Figure 2. Average annual effective dose/person received in 1980 (left panel) and 2006 (right panel) in the United States. The large increase in the use of ionizing 
radiation for medical purposes, in the period 1980-2006, contributed to a total increase from 3.0 mSv in 1980 to 6.2 mSv in 2006. Similar trends are observed 
in other industrialized countries (51).
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the physician. In addition, the identification of biomarkers of 
susceptibility allows screening for sensitive patients, aiding in 
the evaluation of the risk/benefit balance (60).
2. Clinical manifestation and pathology of radiation-induced 
cardiovascular diseases
Overview. As mentioned above, patients treated with radio-
therapy who received doses >40 Gy to part of the heart may 
develop cardiovascular complications later on in life (5). More 
recently, epidemiological findings also point to an excess 
risk of CVD following exposure to lower doses. CVD, also 
commonly referred to as heart disease, comprises a broad range 
of different clinical manifestations. The radiation-induced 
clinical manifestation of CVD is dependent on various factors, 
such as dose, dose rate, the volume of the heart exposed, age 
at exposure, latency of disease, length of follow-up and other 
confounding factors (e.g., smoking and diet) (61). The major 
clinical manifestations of radiation-related CVD (i.e., pericar-
ditis, congestive heart failure and coronary artery disease) are 
discussed below, together with the animal models utilized to 
research these radiation-related pathologies. Ionizing radiation 
may also cause valvular disease, arrhythmias and conduction 
abnormalities, although a direct causal relationship is not 
evidenced (5,62).
Animal models. Next to epidemiology, animal models can be 
useful to investigate radiation-induced cardiovascular disor-
ders. Nevertheless, it should be noted that translation to human 
radiation-induced atherogenic risk should be done with care. 
Indeed, the interaction of radiation exposure with other athero-
genic risk factors is difficult to study in these animal models. 
For instance, gender-related differences in pro-atherogenic 
risk are known to have an influence, as well as lifestyle habits, 
such as smoking, diet and alcohol intake. Since genetic and 
environmental factors play a significant role in cardiovascular 
pathophysiology, it is difficult to match a particular disease 
with a single experimental model (63). Therefore, experi-
menters should select models that best reproduce the aspect of 
disease being investigated. Additional considerations of cost, 
infrastructure and the requirement for specialized personnel 
should also be taken into account. Finally, also the length of the 
reproductive cycle, the availability of genome-wide informa-
tion and the ease of genome manipulation can influence the 
selection of the model.
Due to the long experience of use, the available infrastruc-
ture, the short reproductive cycle and large litters, the mouse is 
often the animal model of choice. In addition, the mouse has 
a well-known genome that is relatively easily to manipulate 
and more recently, infrastructures for non-invasive imaging of 
small animals have become available. However, normal rodents 
are resistant to atherosclerosis since they have low plasma 
levels of pro-atherosclerotic LDL. Therefore, atherosclerosis-
prone animal models have been developed. For example, 
apolipoprotein E (ApoE)-/- and LDL receptor-/- mouse models 
are commonly used (64,65). ApoE is an important glycoprotein 
in the transport and metabolism of lipids and the lack of a func-
tional ApoE gene leads to an altered plasma lipid profile, and 
the rapid development of atherosclerotic lesions (64,65). Mice 
that lack a functional LDL receptor gene also have an altered 
plasma lipid profile, with elevated LDL levels. LDL receptor-
deficient mice will develop atherosclerosis when fed a lipid-rich 
diet (64,65). These mouse model studies can provide valuable 
information regarding the understanding of the cellular and 
molecular pathways underlying radiation-induced development 
and progression of atherosclerosis.
The high-cholesterol diet rabbit models have also been 
used for experimental atherosclerosis (63). Cholesterol causes 
atherosclerotic changes in the rabbit arterial intima, very 
similar to human atherosclerosis. Atherosclerotic lesions also 
develop in normolipidemic rabbits as a result of repeated, 
or continuous intimal injury by catheters or balloons, or by 
nitrogen exposure (66).
The pig is a very good model to study CVD as it has a 
human-like cardiovascular anatomy (63). Pigs develop spon-
taneous atherosclerotic lesions. Porcine models are probably 
the best way to recreate human plaque instability and plaque 
rupture. However, they require voluminous housing with high 
costs, they are difficult to handle, and there are few genomic 
tools available for pigs.
Pericarditis. The earliest sign of radiation-related heart 
disease is acute pericarditis, which occurs already months 
after high-dose irradiation of the heart (>40 Gy). Acute peri-
carditis is the inflammation of the pericardium, the membrane 
that surrounds the heart (Fig. 3), and is characterized by the 
exudation of protein-rich fluid in the pericardial sac. On the 
long-term, this can lead to chronic constrictive pericarditis 
due to fibrin deposition, causing a thickened, rigid pericardial 
sac (2,67). The development of acute pericarditis has also 
been observed in rabbits, rats and dogs after single doses to 
the heart of 16-20 Gy (68-70). These experimental studies 
showed a threshold dose of approximately 15 Gy with a steep 
dose-response relationship (incidence of 100% at 20 Gy). 
Since 1970, advances in radiotherapy treatments have led to a 
significant reduction in both the dose and the volume of the 
heart exposed (3). Therefore, radiation-induced pericarditis is 
uncommon these days.
Coronary artery disease. The obstruction of the blood flow in 
coronary arteries, responsible for blood supply to the heart, is 
referred to as coronary artery disease (9). Mild obstruction due 
to narrowing of the coronary arteries leads to angina (discomfort 
due to ischemia of the heart muscle), whereas severe blockage 
leads to myocardial infarction (heart attack), which on its turn 
leads to acute heart failure. Atherosclerosis is the major under-
lying pathogenesis causing coronary artery disease. It can be 
described as a chronic inflammatory disease of the arterial wall 
in which the build-up of plaques in the intima impairs normal 
vascular functioning (Fig. 4). These plaques are characterized 
by the accumulation of lipids and fibrous elements (71). The 
development and progression of atherosclerosis is a complex 
process with many players. The presence of plaques leads to 
narrowing of the artery and, upon rupture of a plaque, even to 
blockage of the artery (72). Nowadays, coronary artery disease 
is considered the major cardiovascular complication in patients 
that have received radiotherapy for thoracic malignancies (73).
The effect of ionizing radiation on the development and 
progression of atherosclerosis has been investigated in various 
animal models, which has been reviewed (9). For example, 
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Stewart et al examined the development and progression of 
atherosclerotic lesions in ApoE-/- mice after single-dose irradia-
tion (14 Gy) of the neck region (74). There was no major increase 
in the total plaque burden in the exposed carotid arteries, 
although the quality of the plaques was changed, acquiring 
inflammatory characteristics. Indeed, the plaques showed a 
macrophage-rich core, low collagen content and intraplaque 
haemorrhage, which are known to render human atherosclerotic 
plaques unstable and prone to rupture. They also observed the 
presence of atypical swollen endothelial cells. It is hypothesized 
Figure 4. Schematic overview of the development of an atherosclerotic lesion. In all steps, inflammation plays an important role. (A) A healthy artery with a 
well-functioning intact endothelium, a tunica intima, media and adventitia. VSMCs are mainly found in the tunica media but also in the tunica intima. (B) One 
of the initiating steps is the expression of adhesion molecules on the endothelium and the subsequent attraction of inflammatory blood cells (mainly monocytes). 
These monocytes will transmigrate to the intima where they will maturate to macrophages which will then transform to foam cells upon the uptake of ox-LDL. 
(C) Further progression to an atherosclerotic plaque includes the transmigration of VSMCs from the tunica media into the intima and the proliferation of VSMCs 
in the intima. There is also an enhanced production of extracellular matrix molecules, such as collagen, elastin and proteoglycans. Macrophages, foam cells and 
VSMCs can die, and released lipids will accumulate into the central region of the plaque, also denoted the lipid or necrotic core. (D) When a plaque ruptures it 
will induce thrombosis which is the major complication. The blood component will come in contact with the tissue factors present in the interior of the plaque 
triggering the formation of a thrombus which will hamper or even obstruct blood flow. The figure is based on a previous study (167). VSMCs, vascular smooth 
muscle cells; ox-LDL, oxidized low-density lipoprotein.
Figure 3. Overview of the heart anatomy. (A) Illustration of the external anatomy with the major cardiac veins and arteries. (B) More detailed illustration of the 
pericardial sac that surrounds the heart.
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that radiation-induced changes in endothelial function together 
with radiation-induced endothelial cell death and the exposure 
of thrombotic elements of the underlying subendothelium leads 
to chronic inflammation and the development of a vulnerable 
plaque (74). Gene expression profiling of ApoE-/- mice exposed 
to an acute dose of 16 Gy also revealed the upregulation of 
inflammation-related pathways (75). Further research by the 
same group revealed that a more clinically relevant fractioned 
irradiation scheme (20x2 Gy in 4 weeks) also predisposed to the 
formation of an inflammatory plaque (76). Remarkably, acute 
lower dose irradiation (8 Gy) of ApoE-/- mice did not predispose 
to an inflammatory plaque, but did accelerate the development 
of atherosclerosis, as demonstrated by an increased number of 
plaques. Overall, the authors concluded that exposure to high-
dose ionizing radiation accelerates the atherosclerotic process 
in the presence of other risk factors (e.g., high-fat diet), and 
predisposes to the development of a vulnerable inflammatory 
plaque prone to rupture (9).
With low doses and dose rates of radiation the response 
warrants further investigation. Mitchel et al exposed ApoE-/- 
mice to low doses of radiation (0.025-0.5 Gy) at either the 
high (150 mGy/min) or low (1 mGy/min) dose rate (77). 
The mice were exposed at an early stage of atherosclerotic 
disease (2 months old) or at a late stage of atherosclerotic 
disease (8 months old). Doses of 0.025-0.050 Gy, administered 
at both the low- and high-dose rate, induced a protective effect 
by attenuating the formation of new lesions and the increase in 
the size of existing lesions, in mice exposed at an early stage. 
High-dose rate exposure however, increased the progression of 
lesion severity. The effect for mice exposed at a late stage of 
atherosclerotic disease with low-dose rate was similar as that 
for mice exposed at an early stage. On the other hand, high-
dose rate exposures protected against the progression of lesion 
severity, opposite to what was observed in mice exposed at an 
early stage. Additional experiments with ApoE-/- mice with 
reduced p53 functionality (Trp53+/-) revealed an important role 
for p53 in atherosclerosis progression (73). For example, protec-
tive effects of low-dose radiation delivered at both low and 
high dose rate were observed in Trp53 normal mice exposed 
at a late stage of atherosclerotic disease. On the other hand, 
with the same irradiation procedure, detrimental effects were 
observed in Trp53+/- mice exposed at a late stage of atheroscle-
rotic disease. Overall, these findings raised the importance of 
dose-rate effects and p53 functionality on the development of 
atherosclerosis. Furthermore, their findings point out that a 
linear extrapolation of the effects at high doses to low doses is 
not appropriate.
In addition, the effects of chronic low-dose rate vs. acute 
exposures were evaluated in female ApoE-/- mice (60 days) that 
were chronically irradiated for 300 days with gamma-rays at 
two different dose rates (1 and 20 mGy/day), with total accumu-
lated doses of 0.3 or 6 Gy (78). For comparison, age-matched 
ApoE-/- females were acutely exposed to the same doses and 
sacrificed 300 days post-irradiation. Mice acutely exposed to 
0.3 or 6 Gy showed increased atherogenesis compared to the 
age-matched controls, and this effect was persistent. When 
the same doses were delivered at the low-dose rate over 
300 days, again a significant impact on global development of 
atherosclerosis was observed, although at 0.3 Gy effects were 
limited to the descending thoracic aorta. These data suggest 
that a moderate dose of 0.3 Gy can have persistent detrimental 
effects on the cardiovascular system, and that a high dose of 
6 Gy poses high risks at both the high- and low-dose rates. The 
results were clearly non-linear with dose, suggesting that lower 
doses may be more damaging than predicted by a linear dose 
response.
Darby et al formulated two hypotheses for biological 
mechanisms that lead to increased morbidity and mortality 
from coronary artery disease following radiation expo-
sure (5). The first hypothesis states that radiation interacts 
with the pathogenesis of age-related atherosclerosis, as such 
accelerating the development of atherosclerosis. The second 
hypothesis is that radiation increases the lethality of age-
related myocardial infarction by decreasing the heart tolerance 
to acute infarctions as a result of microvascular damage in the 
myocardium. These hypotheses do not stand alone, and both 
macro- and microvascular effects most likely act together to 
produce clinical heart disease (Fig. 5).
Finally, Le Gallic et al investigated the effects of a chronic 
internal exposure to 137Cs on atherosclerosis in predisposed 
ApoE-/- mice (79). Mice were exposed daily to 0, 4, 20 or 
100 kBq/l 137Cs in drinking water, corresponding to range 
of concentrations found in contaminated territories, for 
6 or 9 months. The results suggest that the low-dose chronic 
exposure of 137Cs in ApoE-/- mice enhances atherosclerotic 
lesion stability by inhibiting pro-inflammatory cytokine and 
Figure 5. A theoretical overview of how radiation-induced macrovascular and microvascular pathologies can interact to cause myocardial ischemia, which may 
ultimately develop into clinical heart disease. The figure has been adapted from a previous study (5).
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matrix metalloproteinase (MMP) production, resulting in 
collagen-rich plaques with greater smooth muscle cell and less 
macrophage content.
Congestive heart failure. Congestive heart failure is described 
by a compromised blood pumping function of the heart, due 
to a reduced capacity of the heart muscles, causing under-
perfusion of the body tissues. The underlying pathologies are 
various and include IHD, hypertension, valvular heart disease, 
cardiomyopathies and congenital heart disease (80). Rats that 
received single doses of at least 15 Gy to the heart have been 
shown to develop congestive heart failure within their normal 
lifespan (70). Further radiobiological research has revealed 
an important role for radiation-induced decrease in capillary 
density. Areas of decreased capillary density in the heart are 
characterized by focal loss of the endothelial cell marker, alka-
line phosphatase (81). The progressive reduction of capillary 
density leads to ischemic necrosis, fibrosis and the death of 
cardiac myocytes (muscle cells) in these areas. This myocardial 
degeneration is associated with the first symptomatic signs of 
congestive heart failure, a slight decrease in left ventricle ejec-
tion fraction (2). This reduced cardiac function is maintained in 
a steady-state for a certain period, due to in vivo compensatory 
mechanisms, and fatal congestive heart failure is only observed 
on the long-term (82). Indeed, in ex vivo experiments, cardiac 
function has been shown to deteriorate more rapidly (83).
Myocardial damage has also been observed with lower 
doses. For instance, mild alterations in cardiac function in 
ApoE-/- mice following exposure to 2 Gy have been observed, 
which however did not deteriorate over time (84). Histological 
examination revealed functional damage to the microvascula-
ture as indicated by a focal loss of alkaline phosphatase. More 
recently, Monceau et al exposed the hearts of ApoE-/- and 
wild-type mice to doses of 0.2 Gy (85). Mild but significant 
alterations in cardiac function were observed in both mouse 
strains following exposure to 0.2 Gy. The progression of cardiac 
dysfunction remained, however, stable over the whole study 
period (60 weeks), suggesting the occurrence of compensatory 
mechanisms. Whereas in ApoE-/- mice cardiac damage was 
the consequence of reactive fibrosis in response to inflamma-
tory signalling, this was the consequence of reparative fibrosis 
induced by the loss of cardiac myocytes in wild-type mice. 
Overall, ApoE-/- mice were more radiosensitive. This implies 
that atherosclerosis predisposition enhances and accelerates the 
structural deterioration of the heart following exposure to low 
doses of ionizing radiation, and can thus be considered as a risk 
factor.
3. Molecular and cellular mechanisms underlying the 
observed radiation-induced cardiovascular disorders
The mechanism through which radiation causes heart disease 
is at present unknown, but it acts, at least in part, by causing 
or promoting atherosclerosis. Atherosclerosis is a multifacto-
rial disease, resulting from interactions between genetic and 
environmental factors which may be modified by radiation 
exposure. For radiation doses >1-2 Gy, in vitro and in vivo 
studies have shown that several mechanisms may play a rele-
vant role in radiation-induced cardiovascular effects (3,86-88). 
These effects include endothelial dysfunction, inflammation, 
oxidative stress, alterations in coagulation and platelet activity, 
DNA damage, senescence and cell death. On the contrary, 
low-dose exposure produces both protective and detrimental 
effects, suggesting that multiple mechanisms may influence 
radiation-induced atherosclerosis (42).
Need for experimental studies, particularly in the low-dose 
region. Due to reasons of statistical power, in exposure to 
doses <0.5 Gy, an increased cardiovascular risk cannot be 
evidenced by epidemiology alone, and a better understanding 
of the underlying biological and molecular mechanisms is 
needed. If one proves that there is an increased risk of CVD 
following low-dose exposure, it may have a considerable impact 
on current low-dose health risk estimates.
In contrast to cancer and hereditary effects, knowledge 
of the underlying biological mechanisms for other radiation-
related non-cancer effects in the moderate and low-dose range is 
limited and is assumed to be different from high-dose exposure. 
Therefore, research to understand the mechanisms is urgently 
necessary [Multidisciplinary European Low Dose Initiative, 
Strategic Research Agenda 2015, http://www.melodi-online.
eu/]. Further research is essential to elucidate the low-dose 
effects on the cardiovascular system, and the impact on CVD 
risk. This is, however, not straightforward due to the subtlety of 
low-dose effects and the, most likely, little impact on clinical 
outcome. Apart from the integration of epidemiology and 
biology, as mentioned above, pure radiobiological studies are 
needed. These include mechanistic studies and in vitro studies 
focusing on the elucidation of molecular signaling pathways 
and further in vivo studies. In these studies, attention should 
be paid, not only to dose, but also to dose-rate, fractionated 
exposures and radiation quality.
The role of inflammation. As indicated in Fig. 6, ionizing 
radiation acts on the atherosclerotic process by enhancing 
pro-inflammatory signalling, as reviewed previously (3,89). 
Atherosclerotic plaques are formed by the migration of inflam-
matory cells from the bloodstream into the intima where they 
transform to foam cells. The endothelial expression of adhesion 
molecules plays an important role in this process. Radiation 
has been shown to upregulate E-selectin, intercellular adhe-
sion molecule (ICAM)-1 and vascular cellular adhesion 
molecule (VCAM)-1 following irradiation of endothelial 
cells, in a time- and dose-dependent manner (3). For instance, 
the exposure of endothelial cells to 5 Gy has been shown to 
induce an increase in ICAM-1 and E-selectin expression 
6 h after irradiation (90). Platelet endothelial cell adhesion 
molecule (PECAM)-1, ICAM-1/2 and VCAM-1 were also 
observed to increase in mouse heart cells 10 weeks after local 
thorax irradiation with 8 Gy (91). Interestingly, ICAM-1 and 
VCAM-1 remained upregulated 20 weeks after irradiation. The 
transcription factor, nuclear factor-κB (NF-κB), is involved in 
the radiation-induced upregulation of adhesion molecules (92). 
Apart from the induction of adhesion molecules, the levels 
of cytokines such as interleukin (IL)-6 and IL-8, and other 
inflammatory molecules, such as transforming growth 
factor-β (TGF-β), were shown to increase after high and 
moderate irradiation (93,94). In addition, the Japanese atomic 
bomb survivors' cohort showed signs of a general increased state 
of inflammation, with increased levels of IL-6 and C-reactive 
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protein (CRP) (95). In addition to pro-inflammatory responses, 
there is evidence of pro-thrombotic changes after irradiation 
of the endothelium. For example, several in vitro and in vivo 
studies have demonstrated increased levels of von Willebrand 
factor (VWF) and decreased levels of the anticoagulant, throm-
bomodulin (3,96).
Inflammation was also predicted from a proteomic study as 
an immediate biological response in the cardiac tissue of wild-
type mice exposed to total body irradiation with 3 Gy gamma 
radiation (97). Validated proteomic data concerning cardiac 
microvascular endothelial cells that were isolated from wild-
type mice that received local X-ray heart doses of 8 or 16 Gy 
and that were sacrificed after 16 weeks also strongly suggested 
enhanced inflammation as the main causes of radiation-induced 
long-term vascular dysfunction (98).
There is clinical evidence for anti-inflammatory responses 
of low-dose radiation exposure in individuals who experi-
ence inflammatory diseases. Indeed, for decades, low-dose 
radiotherapy has been used for the treatment of benign inflam-
matory diseases (99,100). However, due to the debate regarding 
possible cancer and non-cancer risks of low-dose radiation 
exposure, the use of low-dose radiotherapy has become unfash-
ionable nowadays (101). In vitro experimental studies have 
confirmed the anti-inflammatory effects of activated endothe-
lial cells after X-irradiation. Indeed, no induction of ICAM-1 
and E-selectin was observed up to 24 h after exposure to 
0.3 and 1 Gy, and was even decreased 4 h after irradiation (90). 
This results in a decreased mononuclear cell adhesion onto the 
endothelium (90,102).
Endothelium as a critical target in radiation-related CVD
Endothelium is the safeguard of normal vascular functioning. 
The endothelium is a single layer of cells that lines the interior 
of the vascular system and has thus a strategic position between 
the blood and the surrounding tissues. Endothelial cells are 
involved in a wide range of physiological processes, such as the 
regulation of vascular tone, vascular permeability, blood coag-
ulation/fibrinolysis and inflammation, which are required to 
maintain proper vascular functioning (Fig. 7) (103). Endothelial 
dysfunction has been observed in patients with atherosclerosis 
and in patients that exhibit CVD risk factors such as smoking, 
dyslipidaemia, obesity and diabetes mellitus (104), and is 
considered one of the first indicators of future cardiovascular 
morbidity and mortality (105-108). It should be noted that 
the endothelium is regarded as a critical target for radiation-
induced CVD.
The endothelium displays phenotypical and functional 
heterogeneity depending on the vascular bed and tissue it is 
situated in (109,110). The major function of arteries and veins 
is the circulation of blood through the body. Capillaries, on the 
other hand, are the major exchange vessels and the capillary 
endothelium is thus very thin and usually fenestrated to ensure 
the optimal diffusion of oxygen and nutrients between the 
blood and underlying tissue (110). Arterial endothelial cells are 
sensitive to disrupted flow at branching points and curvatures 
in the arterial system, which are, consequently, ‘hotspots’ for 
inflammation, coagulation and atherosclerosis (110). A healthy 
arterial endothelium mediates vasodilatation and actively 
suppresses thrombosis, vascular inflammation and inhibits 
vascular smooth muscle cell proliferation and migration (111).
CVD risk factors associated with endothelial dysfunction 
include hypertension, smoking, dyslipidaemia and aging. A 
common underlying cellular mechanism leading to endothe-
lial dysfunction is oxidative stress (112). Oxidative stress is 
defined as an imbalance between the generation of reactive 
oxygen species (ROS) (Fig. 8) and the activity of enzymatic 
and non-enzymatic antioxidant systems (113). At physiological 
levels, ROS are important signalling molecules; however, at 
Figure 6. Overview of the major steps in the pathogenesis of coronary artery disease at the local and systemic level. Flashes indicate events that were also 
observed after radiation exposure, and which are mainly related to inflammation. ECs, endothelial cells; LDL, low-density lipoprotein; IL-6, interleukin-6; CRP, 
C-reactive protein. The figure has been adapted from a previous study (3).
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higher concentrations, ROS cause cellular injury by inducing 
oxidative damage to DNA, lipids and proteins, and may result 
in cell death (114). Apart from cellular damage, oxidative stress 
leads to a decrease in nitric oxide bioavailability, premature 
senescence and mitochondrial dysfunction in endothelial cells.
In vitro endothelial models. The recognition of the endo-
thelium as a central regulator of the cardiovascular system 
significantly enhanced endothelium-related research. One of 
the milestones was the first successful isolation and subsequent 
cultivation and characterization of endothelial cells in vitro, 
in the 1970s (109). Jaffe et al (115) and Gimbrone et al (116) 
reported independently the isolation of endothelial cells from 
human umbilical veins [human umbilical vein endothelial 
cells (HUVECs)]. Since then, many studies have relied on 
the use of HUVECs as they are relatively easy to obtain. 
Although originating from large vessels, HUVECs are unique 
since they exhibit endothelial properties that are intermediate 
between those of large vessels (e.g., the aorta) and those of the 
microvasculature (117). EA.hy926 cells, which are an immor-
talized derivate of HUVECs, are commonly used as well (118). 
However, it should be taken into account when using these cells 
as models for studying the endothelium radiation response, that 
there is a differential response to ionizing radiation in primary 
and immortalized endothelial cells. For example, EA.hy926 
cells are more sensitive to the induction of apoptosis and 
double-strand breaks (DSB) in comparison to the same dose of 
ionizing radiation administered to HUVECs (119).
It should be noted that in vitro endothelial cell models are 
not limited to HUVECs and EA.hy926 cells. Endothelial cells 
may be isolated from other sources in the human body, such 
as the dermal microvasculature, coronary arteries and the 
pulmonary vasculature. However, these are usually not easy to 
obtain and at best only a small amount of material is avail-
able. In addition, these primary cell cultures cannot be kept in 
long-term cultures as they begin to lose their endothelial cell 
characteristics. Therefore, immortalized derivatives of these 
primary cells have been established; for example, EA.hy926 
cells are a derivate of HUVECs. Immortalized cells are charac-
terized by their ability to overcome senescence and can be kept 
in culture for long periods of time (120). These immortalized 
derivatives, however, also exhibit tumour cell characteris-
tics (121). For instance, immortalized human coronary artery 
endothelial cells [transfected with human telomerase reverse 
transcriptase (hTERT)] showed 40% of aneuploidy at a low 
passage number and 100% of aneuploidy at a high passage 
number (121).
Of course, in vitro endothelial models, although useful, are 
not fully representative for the in vivo situation. Yet, advances 
have been made, such as the development of co-culture models 
where endothelial cells are cultured with vascular smooth 
muscle cells to study the atherosclerotic process (122,123). In 
addition, 3-D cultures, where endothelial cells are grown in 
a matrix allowing the formation of tubule-like structures are 
increasingly used to study angiogenesis (124,125). A recent 
review described in detail the use of these co-culture and 
3-D culture models in radiation research (126).
The effect of ionizing radiation on the endothelium. 
Gaining insight into the endothelial response to ionizing 
radiation exposure is not only of importance for understanding 
the development of radiation-related CVD, but also for opti-
mizing cancer treatment. For instance, adverse reactions in 
the surrounding healthy tissue of the tumour are related to 
Figure 7. Overview of the major physiological functions of the arterial endothelium. (A) The endothelium forms a selective barrier regulating the solute flux and 
fluid permeability between the blood and surrounding tissues (105). (B) The formation of a thrombus or blood clot is referred to as coagulation and the breakdown 
of a thrombus is referred to as fibrinolysis. Normal endothelium has anti-thrombotic and pro-fibrinolysis properties, and actively represses platelet adhesion and 
aggregation. Vessel damage or exposure to pro-inflammatory molecules will shift the balance towards more pro-thrombotic/anti-fibrinolysis actions (106,107). 
(C) To regulate vascular tone, the endothelium releases various vasodilatory factors such as NO and EDHF, or vasoconstrictive factors such as ET-1 which will 
modify VSMC function (108). (D) In the case of inflammation, endothelial permeability will be increased. Endothelial cells will also recruit immune cells via 
the expression of adhesion molecules, and mediate their transmigration towards the inner vascular wall (107). The figure is based on a previous study (103). 
ECs, endothelial cells; VSMCs, vascular smooth muscle cells; NO, nitric oxide; EDHF, endothelium-derived hyperpolarizing factor; ET-1, endothelin-1.
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the radiation-response of the microvasculature in the tissue of 
concern. In addition, tumour growth is highly dependent on an 
abundant blood supply, which is maintained by a rich vascular 
network (127). The tumour vasculature thus became a potential 
target in radiotherapy (128). Understanding the effects of radio-
therapy on the tumour endothelium can improve treatment 
regimes. Since the tumour endothelium differs in many aspects 
to the normal endothelium (129), this is not in the scope of this 
review.
Below, an overview is given of classical cellular radiation 
effects and how these may affect endothelial functioning. Next, 
the impact of ionizing radiation on mitochondrial function 
and on senescence is discussed. Finally, attention is paid to 
the contribution of new technologies, such as high throughput 
transcriptomic profiling, allowing a better understanding of the 
underlying molecular signalling pathways:
i) DNA-targeted effects. Ionizing radiation is known to 
induce a wide range of DNA lesions, such as base damage, DNA 
crosslinks, single-strand breaks and DSB in a direct manner, 
but also indirectly through the formation of ROS (130,131). 
Upon DNA damage, a DNA damage response is initiated and 
the cells will activate cell cycle checkpoints which can slow 
down or stop cell cycle progression (132). This gives cells the 
time to repair the damaged DNA or to prevent division when 
chromosomes are damaged or incompletely replicated. If the 
cells fail to repair the DNA, they can go into apoptosis (133).
In particular, DSB will lead to a high lethality of the 
affected cells (134). At the site of DSB damage, the histone 
H2AX is phosphorylated (referred to as γ-H2AX) by kinases, 
such as ataxia telangiectasia mutated (ATM) and ataxia telan-
giectasia and Rad3-related protein (ATR), resulting in the 
formation of γ-H2AX foci (130). These foci will recruit DNA 
repair proteins to the DSB sites. It has been shown that there is 
a 1:1 relationship between the amount of DSB and the γ-H2AX 
foci formed (135). Visualization and quantification of γ-H2AX 
foci has become a standard in assessing radiation-induced 
DNA damage.
Irreparable DSB can cause cellular apoptosis, or prema-
ture senescence (described below). Endothelial apoptosis 
has implications on both the micro- and macrovascular. 
Namely, endothelial cell death in the microvasculature leads 
to a decrease in capillary density. In addition, endothelial 
apoptosis has been related to the development of atheroscle-
rosis (136,137) as it may compromise the regulation of vascular 
tone, and increase the proliferation and migration of vascular 
smooth muscle cells (VSMCs) (138). Furthermore, thrombosis, 
the major complication of atherosclerosis, can be triggered by 
endothelial cell death (137). It should be noted that radiation-
induced endothelial cell apoptosis is not solely a consequence 
of DNA damage. Indeed, ionizing radiation can act on the 
cellular membrane of endothelial cells as well, generating 
ceramide which can induce apoptosis (139).
Whereas high doses are known to induce the apoptosis of 
endothelial cells (140), less is known about the effect of low 
doses. There are indications that, regarding apoptosis, endo-
thelial cells display a non-linear dose relationship. Rödel et al 
demonstrated a discontinuous induction of apoptosis with a 
relative maximum at 0.3 and 3 Gy and a relative minimum 
at 0.5 Gy in endothelial cells stimulated with tumor necrosis 
factor (TNF)-α (141). Another study showed no increase in 
apoptotic endothelial cells following exposure to 0.2 Gy, but 
only following exposure to 5 Gy (142). In a different study, 
a subtle but a significant increase in DSBs was observed in 
HUVECs and EA.hy926 cells 30 min after exposure to 0.05 Gy. 
In addition, irradiation with 0.05 and 0.1 Gy induced relatively 
more DSB/Gy in comparison to 0.5 and 2 Gy. Furthermore, a 
dose-dependent increase in apoptotic cells was observed, down 
to 0.5 Gy in HUVECs and 0.1 Gy in EA.hy926 cells (119).
ii) Radiation-induced mitochondrial dysfunction and 
metabolic changes. There is a great deal of interest in radiation-
induced mitochondrial dysfunction, seeing the implications 
it has on CVD (143). Mitochondrial dysfunction is closely 
related to oxidative stress, being both a target and a source of 
ROS. Initially, ionizing radiation causes the formation of water 
Figure 8. Electron structures of common ROS. Below each structure, its name and chemical formula are given. • represents an unpaired electron. ROS, reactive 
oxygen species.
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radiolysis products, including hydroxyl radicals (•OH), hydro-
peroxyl radicals (HO2•) and hydrogen peroxide (H2O2) (Fig. 8). 
These are unstable and disappear within <10-3 sec, apart from 
H2O2 (144). However, following irradiation, oxidative stress is 
observed after longer time periods due to an increase in the 
endogenous cellular production of ROS (145). The mitochondria 
are believed to be the major source of these radiation-induced 
secondary ROS, although other sources may contribute as well. 
For instance, Leach et al (147) demonstrated that, between 
1 and 10 Gy, the amount of ROS-producing cells increased with 
the dose, which they suggested was dependent on the radiation-
induced propagation of mitochondrial permeability transition 
via a Ca2+-dependent mechanism (146).
Since the mitochondria, in particular mitochondrial DNA 
(mtDNA), are also a critical target of ROS, measurements of 
mtDNA damage have been used to determine the deleterious 
effects of ionizing radiation. The increased accumulation of 
common deletion (CD) following exposure to ionizing radiation 
has been detected in various studies (148-150). The measure-
ment of CD by quantitative (real-time) polymerase chain 
reaction (PCR) has been proposed as a sensitive marker to 
detect low levels of oxidative damage to the mtDNA (148). An 
increased accumulation of the CD has been observed in several 
human fibroblast cell lines following exposure to doses as low 
as 0.1 Gy (150). Interestingly, increased accumulation of the CD 
was also observed in bystander cells, i.e., cells that were cultured 
in conditioned medium derived from 0.1 Gy-irradiated cells.
However, the question of whether low doses of ionizing 
radiation have an impact on mitochondrial function has not 
been fully resolved yet. For instance, an in vivo study by 
Barjaktarovic et al investigated the effects in vivo of 0.2 and 
2 Gy local heart irradiation on cardiac mitochondria (151). In 
another study of theirs, four weeks after exposure, cardiac mito-
chondria were isolated from C57BL/6N mice and subjected to 
proteomic and functional analysis. Whereas with 2 Gy both 
functional impairment of mitochondria and alterations in the 
mitochondrial proteome were observed, only a few alterations 
in the mitochondrial proteome and no effect on mitochondrial 
function was observed with 0.2 Gy. After 40 weeks, the respira-
tory capacity of irradiated C57BL/6 cardiac mitochondria was 
significantly reduced at 40 weeks (152). In parallel, protein 
carbonylation was increased, suggesting enhanced oxidative 
stress. In addition, considerable alterations were found in the 
levels of proteins of the mitochondria-associated cytoskeleton, 
respiratory chain, ion transport and lipid metabolism. High-
dose radiation induced similar, but less pronounced effects in 
the mitochondrial proteome of ApoE-/- mice after 40 weeks 
upon local heart X-irradiation. In ApoE-/-mice, no significant 
change was observed in mitochondrial respiration or protein 
carbonylation. The dose of 0.2 Gy had no significant effects on 
cardiac mitochondria.
Alterations in cardiac proteins involved in lipid metabolism 
and oxidative phosphorylation were shown in a proteomic study 
of mice that received local heart irradiation with X-ray doses of 
8 and 16 Gy and were sacrificed at week 16 after exposure (153). 
Ionizing radiation markedly altered the phosphorylation and 
ubiquitination status of peroxisome proliferator-activated 
receptor (PPAR) α, a transcriptional regulator of lipid metabo-
lism in heart tissue with a possible role in the development 
of CVD. This was reflected as a decreased expression of its 
target genes involved in energy metabolism and mitochondrial 
respiratory chain confirming the proteomics data. In addi-
tion, other proteomic studies of the same group suggested the 
deregulation of mitochondrial proteins and proteins involved in 
oxidative phosphorylation or glycolysis/gluconeogenesis either 
in cells (2.5 Gy gamma-irradiation of EA.hy926 cells, evaluation 
after 4 and 24 h) or mouse hearts (total body irradiation with 3 Gy 
gamma-ray and sacrificed after 5-24 h) (97). Furthermore, post-
translational acetylation alterations in primary human cardiac 
microvascular endothelial cells 4 h after a gamma radiation 
dose of 2 Gy indicated radiation-induced changes in, amongst 
others, mitochondrial proteins (154). Finally, an impaired energy 
metabolism and perturbation of the insulin/insulin-like growth 
factor (IGF)-PI3K-Akt signalling pathway was identified by 
validated proteomic data in cardiac microvascular endothelial 
cells from wild-type mice that received a local X-ray dose of 8 or 
16 Gy and that were sacrificed after 16 weeks (98).
iii) Radiation-induced premature senescence. Ionizing 
radiation is a well-known stressor that induces premature senes-
cence in cells (158). The culprit is most likely severe irreparable 
radiation-induced DSB (155), although radiation-induced 
accelerated telomere attrition has also been suggested (156). In 
addition, oxidative stress is a major player in radiation-induced 
senescence and is involved in both radiation-induced DNA 
damage and accelerated telomere attrition (156-158).
In several in vitro studies, it has been demonstrated that 
ionizing radiation induces endothelial cell senescence, mainly 
with exposure to higher doses of radiation (159-162). Most 
studies confirm that radiation-induced premature endothelial 
senescence is implemented by the engagement of the clas-
sical DNA damage response pathways, similar to replicative 
senescence (159,160,163). For instance, Kim et al observed that 
exposure to 4 Gy led to a senescent phenotype in endothelial 
cells. An increased formation of γ-H2AX foci and he conse-
quent activation of the DNA damage response was observed, 
as indicated by the upregulation of p53 and p21 and the down-
regulation of cyclins and Rb phosphorylation (162).
Interesting studies were carried out to examine the 
effect of chronic low-dose rate irradiation (1.4, 2.4 and 
4.1 mGy/h) (164,165). Endothelial cells were exposed for 
1, 3 and 6 weeks, to determine whether chronic low-dose 
rate radiation changes the onset of replicative senescence, as 
measured by SA-β-gal activity and the proliferation rate. Their 
findings are indicative of a threshold dose rate for the induc-
tion of premature senescence. Exposure to 1.4 mGy/h did not 
accelerate the onset of senescence, whereas exposure to 2.4 and 
4.1 mGy/h did. Remarkably, a senescent profile was observed 
when the accumulated doses received by the cells reached 
4 Gy. Proteomic analysis revealed a role for radiation-induced 
oxidative stress and DNA damage, resulting in the induction 
of the p53/p21 pathway (164). A role of the PI3K/Akt/mTOR 
pathway was also suggested (165).
In a related transcriptomic study, the gene expression profile 
was studied in HUVECs that were exposed to chronic low-dose 
rate ionizing radiation (1.4 and 4.1 mGy/h) for either 1, 3 or 
6 weeks. Using a dual approach, combining single gene expres-
sion analysis and Gene Set Enrichment Analysis, an early stress 
response with p53 signalling, cell cycle changes, DNA repair 
and apoptosis were observed after 1 week of exposure to both 
dose rates. This early response disappeared after 3 and 6 weeks 
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of chronic low-dose rate radiation exposure (4.1 mGy/h), and 
was replaced by the development of an inflammation-related 
profile. After a period of 6 weeks, the early stress response 
along with the associated inflammation led to the induction of 
premature senescence in the 4.1 mGy/h-exposed samples. This 
premature senescence was stress-related and showed a possible 
role of IGF binding protein 5 signalling, known to be involved 
in the regulation of cellular senescence (166).
Validated proteomic data concerning cardiac microvascular 
endothelial cells that were isolated form wild-type mice that 
received local X-ray heart doses of 8 or 16 Gy and that were 
sacrificed after 16 weeks also strongly suggested enhanced 
inflammation as the main causes of radiation-induced long-
term vascular dysfunction (98).
4. Conclusion
We are all exposed to ionizing radiation, from naturally occur-
ring substances with unstable nuclei to X-rays for medical 
diagnostics. A pressing question is whether or not exposure to 
these very low doses can cause damage to our health. From 
epidemiological studies, it is suggested that CVD may be 
a health risk associated with radiation exposure. However, 
with exposure to doses <0.5 Gy, an increased risk cannot be 
evidenced by epidemiology alone, and a better understanding 
of the underlying biological and molecular mechanisms is 
needed. In this way, the current radiation protection system 
can be refined, making it possible to more accurately assess 
the cardiovascular risk in the low-dose region. The only way 
to unequivocally demonstrate the cardiovascular effects of 
low-dose ionizing radiation is to use dedicated or specialized 
in vitro and in vivo systems representing the cardiovascular 
system. In these systems, the endothelium is believed to be a 
critical target of ionizing radiation exposure due to its crucial 
role in maintaining the vascular homeostasis in the human 
body. Over the years, many underlying causes of endothelial 
dysfunction following exposure to ionizing radiation have been 
studied, such as nitric oxide bioavailability, premature cell 
senescence and dysfunction of the mitochondria. However, 
results in these fields are ambiguous and more research is 
required to resolve their inconsistencies. These efforts are not in 
vain, since not only can these findings be used to ameliorate the 
current radiation protection system, but they can also be used to 
devise cardiovascular risk-reducing strategies, which can limit 
the number of patients suffering from CVD worldwide.
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